Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-11 pm EST			5-day change	1st Jan Change
240.86 ^USD	+1.05%		+2.73%	+16.39%

Feb. 11	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
Feb. 09	Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna	RE

Health Care Up After Trump Rescinds Tariff Threats - Health Care Roundup

Published on 01/21/2026 at 05:36 pm EST

Dow Jones

JOHNSON & JOHNSON

+1.05%

NOVO NORDISK A/S

+0.75%

SANOFI

-5.12%

Health-care companies rose after President Trump rescinded a threat to impose tariffs on several major European nations.

Strong demand for cancer and autoimmune treatments more than offset the sales hit from a key drug-patent loss as health-care conglomerate Johnson & Johnson posted fourth-quarter earnings growth.

Stelara, a treatment for skin and gut conditions, lost patent protection last year. Shares of international drug makers such as French firm Sanofi and Danish giant Novo Nordisk rose or came off their lows following Trump's assertion on the Truth Social network that he had agreed on the "framework" of a deal to build missile defenses on Greenland.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-21-26 1735ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
JOHNSON & JOHNSON	240.86USD	+1.05%	+2.73%	580B
NOVO NORDISK A/S	309.00DKK	+0.75%	+10.30%	216B
SANOFI	78.33EUR	-5.12%	-3.47%	118B

Latest news about Johnson & Johnson

Feb. 11	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
Feb. 09	Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna	RE
Feb. 09	NervGen Pharma Corp. Appoints Adam Rogers as President, Effective February 9, 2026	CI
Feb. 09	NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026	CI
Feb. 09	As AI enters the operating room, reports arise of botched surgeries and misidentified body parts	RE
Feb. 07	Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium	CI
Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 05	Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
Feb. 04	AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss	RE
Feb. 04	AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss	RE
Feb. 04	Freshpet, Inc. Announces Appointment of Ana Lopez as Senior Vice President of Supply Chain, Effective February 2, 2026	CI
Feb. 03	Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says	MT
Feb. 03	Rigel Pharmaceuticals, Inc. Appoints Michael P. Miller to Its Board of Directors	CI
Feb. 03	Bristol Myers Squibb launches campaign with Johnson & Johnson	RE
Feb. 03	RBC Raises Price Target on Johnson & Johnson to $255 From $240, Keeps Outperform Rating	MT
Feb. 02	STAAR Surgical Company Announces Interim Co-CEO Appointments, Effective February 1, 2026	CI
Feb. 02	Johnson & Johnson Announces New Real World Head-To-Head Analysis Demonstrating That Patients with Metastatic Castration-sensitive Prostate Cancer Initiating ERLEADA®	CI
Jan. 30	HSBC Adjusts Johnson & Johnson PT to $265 From $240, Maintains Buy Rating	MT
Jan. 30	Johnson & Johnson Gets Positive EU Panel Opinion for Akeega in Metastatic Prostate Cancer	MT
Jan. 30	Johnson & Johnson receives CHMP positive opinion for AKEEGA	RE
Jan. 29	US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy	RE
Jan. 29	Daiwa Securities Adjusts Price Target on Johnson & Johnson to $237 From $203, Maintains Outperform Rating	MT
Jan. 29	Johnson & Johnson Insider Sold Shares Worth $22,122,893, According to a Recent SEC Filing	MT
Jan. 28	BioNTech SE Announces Appointment of Kylie Jimenez to the Management Board as Chief People Officer, Effective March 1, 2026	CI

Chart Johnson & Johnson

Duration

Period

JNJ: Dynamic Chart

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Feb. 23 -

More about the company